| Media Contracts Completed | Quarterly Revenue | Revenue / Media Contract | ||||||||||
| Quarter Ending March 31, 2022 | 134 | $ | 485,065 | $ | 3,620 | |||||||
| Quarter Ending June 30, 2022 | 249 | 339,423 | 1,363 | |||||||||
| Quarter Ending September 30, 2022 | 417 | 124,987 | 300 | |||||||||
| Quarter Ending December 31, 2022 | 316 | 374,830 | 1,186 | |||||||||
| Year Ending December 31, 2022 | 1,116 | $ | 1,324,305 | $ | 1,187 | |||||||
| Quarter Ending March 31, 2023 | 170 | $ | 138,037 | $ | 812 | |||||||
| Quarter Ending June 30, 2023 | 163 | 88,977 | 546 | |||||||||
| Quarter Ending September 30, 2023 | 155 | 97,820 | 631 | |||||||||
| Quarter Ending December 31, 2023 | 202 | 331,266 | 1,640 | |||||||||
| Year Ending December 31, 2023 | 690 | $ | 656,100 | $ | 951 | |||||||
| For the | For the | |||||||
| Year Ended | Year Ended | |||||||
| December 31, | December 31, | |||||||
| 2023 | 2022 | |||||||
| Net Loss | $ | (8,724,863) | $ | (11,114,179) | ||||
| Reconciliation of Adjusted EBITDA Loss to Net Loss: | ||||||||
| Depreciation and amortization | $ | (792,949) | $ | (199,225) | ||||
| Share-based compensation | (580,002) | (2,301,735) | ||||||
| Deferred offering cost write-off | (1,026,012) | - | ||||||
| Forfeiture of Deferred Compensation | 769,839 | - | ||||||
| Interest expense | (960,898) | (1,563,162) | ||||||
| Total Adjustments of EBITDA Loss to Net Loss | $ | (2,590,022) | $ | (4,064,122) | ||||
| Adjusted EBITDA | $ | (6,134,841) | $ | (7,050,057) | ||||
| Common Stock | Additional | |||||||||||||||||||
| Shares Outstanding | Amount | Paid in Capital | Accumulated Deficit | Total | ||||||||||||||||
| Balance - January 1, 2022 | 10,243,442 | $ | 1,024 | $ | 38,089,295 | $ | (42,110,073) | $ | (4,019,754) | |||||||||||
| Share-based compensation | - | - | 1,694,344 | - | 1,694,344 | |||||||||||||||
| Issuance of common stock pursuant to restricted stock awards (share-based compensation) | 290,000 | 29 | 607,362 | - | 607,391 | |||||||||||||||
| Conversion of Convertible 2021 Convertible Note Payable and accrued interest to common shares | 1,594,807 | 159 | 7,973,848 | - | 7,974,007 | |||||||||||||||
| Deemed Dividend from Inducement to Exercise Warrants | - | - | 28,600 | (28,600) | - | |||||||||||||||
| Issuance of common stock pursuant to exercise of warrants | 235,693 | 24 | 1,285,809 | - | 1,285,833 | |||||||||||||||
| Deferred debt discount on 2022 convertible notes payable | - | - | 324,213 | - | 324,213 | |||||||||||||||
| Issuance of common stock pursuant to exercise of employee stock options | 6,060 | 1 | 19,975 | - | 19,976 | |||||||||||||||
| Net Loss | - | - | - | (11,114,179) | (11,114,179) | |||||||||||||||
| Balance - December 31, 2022 | 12,370,002 | $ | 1,237 | $ | 50,023,446 | $ | (53,252,852) | $ | (3,228,169) | |||||||||||
| Balance - January 1, 2023 | 12,370,002 | $ | 1,237 | $ | 50,023,446 | $ | (53,252,852) | $ | (3,228,169) | |||||||||||
| Share-based compensation | - | - | 496,141 | - | 496,141 | |||||||||||||||
| Issuance of common stock pursuant to restricted stock awards | (250,000) | (25) | 83,886 | - | 83,861 | |||||||||||||||
| Conversion of Convertible Note Payable and accrued interest to common shares | 1,441,497 | 144 | 2,719,197 | - | 2,719,341 | |||||||||||||||
| Conversion of Shareholder Note and accrued interest to common shares | 50,328 | 6 | 201,309 | - | 201,315 | |||||||||||||||
| Deferred debt discount on 2022 convertible notes payable | - | - | 720,975 | - | 720,975 | |||||||||||||||
| Issuance of common stock pursuant to exercise of employee stock options | - | - | - | - | - | |||||||||||||||
| Issuance of common stock for patents acquisition | 2,000,000 | 200 | 3,999,800 | - | 4,000,000 | |||||||||||||||
| Net Loss | - | - | (8,724,863) | (8,724,863) | ||||||||||||||||
| Balance - December 31, 2023 | 15,611,827 | $ | 1,562 | $ | 58,244,754 | $ | (61,977,715) | $ | (3,731,399) | |||||||||||
| Cost of sales | $ | 62,099 | ||
| Technology and development | 59,734 | |||
| Sales, general and administrative | 2,179,902 | |||
| Total | $ | 2,301,735 |
| Options | Weighted Average Exercise Price | Remaining Life | Aggregate Intrinsic Value for the Activity During the Years | |||||||||||||
| Balance, January 1, 2022 | 3,116,626 | $ | 4.44 | 7.0 | 0 | |||||||||||
| Granted | 517,500 | |||||||||||||||
| Exercised | (6,060) | |||||||||||||||
| (Forfeiture) | (555,000) | |||||||||||||||
| Balance, December 31, 2022 | 3,073,066 | $ | 5.22 | 6.0 | 0 | |||||||||||
| Exercisable, December 31, 2022 | 2,711,448 | $ | 3.40 | 7.1 | 0 | |||||||||||
| Balance, January 1, 2023 | 3,073,066 | $ | 5.22 | 6.0 | 0 | |||||||||||
| Granted | ||||||||||||||||
| Exercised | ||||||||||||||||
| (Forfeiture) | (139,028) | |||||||||||||||
| Balance, December 31, 2023 | 2,934,038 | $ | 3.46 | 5.1 | 0 | |||||||||||
| Exercisable, December 31, 2023 | 2,810,820 | $ | 5.25 | 2.9 | 0 | |||||||||||
